SFSIG
SIOX

San Francisco Sentry Investment Group’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

San Francisco Sentry Investment Group’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-638
Closed -$27K – 943
2017
Q4 		$27K Buy
638
+57
+10% +$2.56K 0.01% 523
2017
Q3 		$32K Buy
581
+550
+1,774% +$92.8K 0.01% 489
2017
Q2 		$6K Buy
+31
New +$5.43K ﹤0.01% 590

Other funds holding SIOX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

San Francisco Sentry Investment Group's SIOX Position: Q1 2018 in Review

San Francisco Sentry Investment Group sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2018, closing a stake of 638 shares — an estimated $27K sold.

San Francisco Sentry Investment Group first reported a position in SIOX in Q2 2017 and held it in 3 quarters. The position peaked at $32K in Q3 2017. 81 funds tracked by Wall St. Rank hold SIOX as of Q1 2018.

  • San Francisco Sentry Investment Group reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • San Francisco Sentry Investment Group sold 638 Sio Gene Therapies Inc. Common Stock shares in Q1 2018, an estimated $27K.
  • San Francisco Sentry Investment Group first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2017 and held it in 3 quarters.
  • San Francisco Sentry Investment Group's Sio Gene Therapies Inc. Common Stock position peaked at $32K in Q3 2017.
  • 81 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2018.

Based on San Francisco Sentry Investment Group's 13F filing for Q1 2018, filed 4 May 2018.